Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Ark Invest founder Cathie Wood bought Tesla (TSLA), SoFi Technologies (SOFI), and Recursion Pharmaceuticals (RXRX) across ARK ETFs. Tesla deliveries rose 25% YoY to 480,126 vehicles; shares fell ~7.5% after Q2 results. SoFi added members and reported 41% adjusted revenue growth. Recursion is a clinical-stage AI drug developer with $66M trailing revenue.
How this was made
The 30-second read
Why it matters
For TSLA, the key trade question is whether delivery outperformance offsets incentive-driven margin pressure into the July 22 earnings report. For SOFI, the trade question is whether growth and EBITDA margin can sustain while valuation remains elevated. For RXRX, the trade question is catalyst timing in a pre-revenue/early-stage profile; the article provides no new clinical datapoint.
Market read
This is more of a positioning/conviction narrative than a new fundamental disclosure; it may influence sentiment but lacks fresh, decision-grade catalysts in the text.
What to watch
The article doesn’t provide new guidance, trial readouts, or regulatory milestones—so traders may be over-weighting a fund’s action relative to upcoming company-specific catalysts (TSLA earnings; any SoFi/Recursion updates not detailed here).
Background
The piece is a Cathie Wood/Ark Invest portfolio activity write-up, using recent company updates (TSLA deliveries; SOFI operating metrics) to justify purchases.
Ticker impact
Ark bought Tesla after Q2 production/delivery results showed 480,126 deliveries, up 25% YoY, despite the stock falling ~7.5% on Thursday.
Near-term volatility likely into July 22 as traders weigh delivery strength vs. incentive-driven margin pressure.
Deliveries beat consensus in the text, but the piece explicitly raises the key counterpoint (promotions/incentives hurting margins) and ties the next decision point to the scheduled earnings date.
Ark added to SoFi daily this week, citing 14.7M members and 41% adjusted revenue growth with a 31% adjusted EBITDA margin.
Supportive for dip-buyers, but upside may be capped unless growth or margins re-accelerate enough to justify the forward multiple.
The text provides specific operating metrics (members, adjusted growth, EBITDA margin) and valuation context (forward earnings and next-year targets), which can influence positioning over weeks.
Ark bought Recursion Pharmaceuticals, highlighting its AI-driven drug discovery approach and that Ark owns ~$115M (~5% of shares outstanding).
Price likely remains catalyst-driven; absent new clinical/regulatory data in the text, near-term trading may be sentiment/positioning rather than fundamentals.
The article discloses portfolio sizing and business model, but does not provide any new trial results, approvals, or regulatory events—only general stage/financial context.
Market effects
Reinforces read-through that investors are willing to pay for growth with profitability (fintech) and to underwrite delivery momentum (EV) despite margin/incentive concerns.
TSLA discussion specifically points to Europe demand dynamics tied to fuel-price spikes and promotional activity.
Limited; the story is primarily portfolio/stock-specific rather than a broad macro or cross-market shock.
Counterpoint
Ark’s buying may reflect portfolio rebalancing or conviction rather than new information; for TSLA, delivery strength could still translate into weaker margins due to incentives.
Key entities
- asset_managerArk Invest
Cathie Wood’s firm making the reported purchases across Ark ETFs.
- companyTesla
Ark added after Q2 deliveries beat expectations; margin risk flagged ahead of July 22 earnings.
- companySoFi Technologies
Ark added daily this week, citing member growth and adjusted revenue/EBITDA metrics.
- companyRecursion Pharmaceuticals
Ark increased exposure to an AI drug discovery platform with ongoing losses and limited revenue.
